Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

THE PHARMACOLOGY OF 2-(ETHYLAMINO)-2-(2-THIENYL)-CYCLOHEXANONE·HCl (CI-634)

GRAHAM CHEN, CHARLES R. ENSOR and BARBARA BOHNER
Journal of Pharmacology and Experimental Therapeutics July 1969, 168 (1) 171-179;
GRAHAM CHEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHARLES R. ENSOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BARBARA BOHNER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

CI-634 acts principally on the central nervous system. Species of animals vary markedly in response to the drug. Excitement and ataxia prevailed in mice and rats at low doses of 01-634. At high doses, surgical anesthesia occurred in monkeys and cats, and either light anesthesia or transitory clonic seizures occurred in dogs. Anesthesia was induced in monkeys and cats within 2 to 3 mm after im. administration. No cumulative effect or tolerance development resulted upon repeated administration of CI-634. Catalepsy was the characteristic effect of CI-634 in all animal species. At cataleptic doses, it augmented the depth and duration of anesthesia produced by other anesthetic agents without causing an increase in respiratory depression. It produced slight hypertension and tachycardia in unanesthetized dogs. Only negative chronotropic and inotropic effects of CI-634 were observed in the isolated rabbit heart. The lack of a direct sympathomimetic effect of CI-634 was evident by its failure to influence the blood pressure responses to norepinephrine and phenethylamine in anesthetized dogs and by its failure to increase the perfusion pressure in the autoperfused hindquarter of the dog after direct i.a. injection. The hypertension and tachycardia produced by CI-634 appeared to be the result of an influence on central cardiovascular regulatory mechanisms.

Footnotes

    • Received April 15, 1968.
    • Accepted February 14, 1969.
  • © 1969, by The Williams & Wilkins Company

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 168, Issue 1
1 Jul 1969
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
THE PHARMACOLOGY OF 2-(ETHYLAMINO)-2-(2-THIENYL)-CYCLOHEXANONE·HCl (CI-634)
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

THE PHARMACOLOGY OF 2-(ETHYLAMINO)-2-(2-THIENYL)-CYCLOHEXANONE·HCl (CI-634)

GRAHAM CHEN, CHARLES R. ENSOR and BARBARA BOHNER
Journal of Pharmacology and Experimental Therapeutics July 1, 1969, 168 (1) 171-179;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

THE PHARMACOLOGY OF 2-(ETHYLAMINO)-2-(2-THIENYL)-CYCLOHEXANONE·HCl (CI-634)

GRAHAM CHEN, CHARLES R. ENSOR and BARBARA BOHNER
Journal of Pharmacology and Experimental Therapeutics July 1, 1969, 168 (1) 171-179;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism
  • Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals?
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics